<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: therapeutic", fill: "#d3d3d3"},
{source: "1: therapeutic", target: "1: intervention", fill: "#d3d3d3"},
{source: "1: therapeutic", target: "2: discovery", fill: "#ff2400"},
{source: "2: discovery", target: "2: development", fill: "#ff2400"},
{source: "2: development", target: "2: inherently risky", fill: "#ff2400"},
{source: "2: discovery", target: "4: proposed drug products", fill: "#ed1c24"},
{source: "4: proposed drug products", target: "4: drug research programs", fill: "#ed1c24"},
{source: "4: drug research programs", target: "4: early stages", fill: "#ed1c24"},
{source: "4: early stages", target: "4: significant timeconsuming", fill: "#ed1c24"},
{source: "4: significant timeconsuming", target: "4: development testing", fill: "#ed1c24"},
{source: "4: development testing", target: "4: regulatory approvals", fill: "#ed1c24"},
{source: "4: proposed drug products", target: "5: product candidates will", fill: "#98fb98"},
{source: "5: product candidates will", target: "5: commercially available", fill: "#98fb98"},
{source: "5: product candidates will", target: "10: product candidates through", fill: "#014421"},
{source: "10: product candidates through", target: "10: consuming preclinical", fill: "#014421"},
{source: "10: consuming preclinical", target: "10: clinical trials", fill: "#014421"},
{source: "10: clinical trials", target: "10: governed by exacting regulations", fill: "#014421"},
{source: "10: product candidates through", target: "11: product candidates", fill: "#c71585"},
{source: "11: product candidates", target: "11: preclinical stages", fill: "#c71585"},
{source: "11: preclinical stages", target: "11: development", fill: "#c71585"},
{source: "11: product candidates", target: "14: regulatory approvals", fill: "#fffff0"},
{source: "14: regulatory approvals", target: "14: commercial sale", fill: "#fffff0"},
{source: "14: commercial sale", target: "14: clinical trials human testing", fill: "#fffff0"},
{source: "14: clinical trials human testing", target: "14: effective", fill: "#fffff0"},
{source: "14: effective", target: "14: each target indication", fill: "#fffff0"},
{source: "14: regulatory approvals", target: "21: regulatory", fill: "#4b5320"},
{source: "21: regulatory", target: "21: commercialize", fill: "#4b5320"},
{source: "21: commercialize", target: "21: candidates", fill: "#4b5320"},
{source: "21: regulatory", target: "23: numerous unforeseen", fill: "#add8e6"},
{source: "23: numerous unforeseen", target: "23: events during", fill: "#add8e6"},
{source: "23: events during", target: "23: prevent us from", fill: "#add8e6"},
{source: "23: prevent us from", target: "23: regulatory", fill: "#add8e6"},
{source: "23: regulatory", target: "23: commercializing", fill: "#add8e6"},
{source: "23: commercializing", target: "23: product candidates", fill: "#add8e6"},
{source: "23: product candidates", target: "23: clinical trials", fill: "#add8e6"},
{source: "23: clinical trials", target: "23: inconclusive", fill: "#add8e6"},
{source: "23: inconclusive", target: "23: regulators may", fill: "#add8e6"},
{source: "23: regulators may", target: "23: conduct additional", fill: "#add8e6"},
{source: "23: conduct additional", target: "23: clinical andor preclinical testing", fill: "#add8e6"},
{source: "23: clinical andor preclinical testing", target: "23: abandon programs", fill: "#add8e6"},
{source: "23: abandon programs", target: "23: statistical significance", fill: "#add8e6"},
{source: "23: statistical significance", target: "23: regulatory agencies", fill: "#add8e6"},
{source: "23: regulatory agencies", target: "23: enrollment", fill: "#add8e6"},
{source: "23: enrollment", target: "23: product candidates may", fill: "#add8e6"},
{source: "23: product candidates may", target: "23: slower than", fill: "#add8e6"},
{source: "23: slower than", target: "23: significant delays", fill: "#add8e6"},
{source: "23: significant delays", target: "23: regulators may suspend", fill: "#add8e6"},
{source: "23: regulators may suspend", target: "23: participating patients", fill: "#add8e6"},
{source: "23: participating patients", target: "23: health risks", fill: "#add8e6"},
{source: "23: health risks", target: "23: product candidates on patients may", fill: "#add8e6"},
{source: "23: product candidates on patients may", target: "23: characteristics", fill: "#add8e6"},
{source: "23: characteristics", target: "23: preclude regulatory approval", fill: "#add8e6"},
{source: "23: preclude regulatory approval", target: "23: commercial use", fill: "#add8e6"},
{source: "23: commercial use", target: "23: regulatory agencies may lack", fill: "#add8e6"},
{source: "23: regulatory agencies may lack", target: "23: drugs based on", fill: "#add8e6"},
{source: "23: numerous unforeseen", target: "32: rely on third parties", fill: "#d3003f"},
{source: "32: rely on third parties", target: "32: conduct most", fill: "#d3003f"},
{source: "32: conduct most", target: "32: clinical trials", fill: "#d3003f"},
{source: "32: clinical trials", target: "32: obligations", fill: "#d3003f"},
{source: "32: obligations", target: "32: competent manner may", fill: "#d3003f"},
{source: "32: competent manner may", target: "32: delay development", fill: "#d3003f"},
{source: "32: delay development", target: "32: commercialization", fill: "#d3003f"},
{source: "32: commercialization", target: "32: product candidates", fill: "#d3003f"},
{source: "32: rely on third parties", target: "41: Integrating ", fill: "#062a78"},
{source: "41: Integrating ", target: "41: technology", fill: "#062a78"},
{source: "41: technology", target: "41: timeconsuming", fill: "#062a78"},
{source: "41: timeconsuming", target: "41: management", fill: "#062a78"},
{source: "41: Integrating ", target: "START_HERE", fill: "#062a78"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_management">Technology management</a></td>
      <td>Technology management is a set of management disciplines that allows organizations to manage their technological fundamentals to create customer advantage. Typical concepts used in technology management are:\n\nTechnology strategy (a logic or role of technology in organization),\nTechnology forecasting (identification of possible relevant technologies for the organization, possibly through technology scouting),\nTechnology roadmap (mapping technologies to business and market needs), and\nTechnology project portfolio (a set of projects under development) and technology portfolio (a set of technologies in use).The role of the technology management function in an organization is to understand the value of certain technology for the organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ARQULE INC      ITEM 1A        RISK FACTORS       RISKS RELATING TO OUR BUSINESS STRATEGY AND OPERATIONS       Development of our products is at an early stage and is <font color="blue">based on</font> scientific     platforms that are unproven approaches to <font color="blue">therapeutic</font> <font color="blue">intervention</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">discovery</font> and <font color="blue">development</font> of drugs is <font color="blue">inherently risky</font> and involves a     high  rate of failure</td>
    </tr>
    <tr>
      <td><font color="blue">Discovering </font>and developing commercial drugs are     <font color="blue">relatively</font> new to us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">proposed drug products</font> and <font color="blue">drug research programs</font>     are in <font color="blue">early stages</font> and require <font color="blue">significant</font>, time-consuming and costly     research and <font color="blue">development</font>, testing and <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font></td>
    </tr>
    <tr>
      <td>We do not expect     that these <font color="blue"><font color="blue">product candidate</font>s will</font> be <font color="blue"><font color="blue">commercially</font> available</font> for several     years, if ever</td>
    </tr>
    <tr>
      <td>Our  lead  <font color="blue">product candidate</font>, ARQ 501, is <font color="blue">based on</font> our <font color="blue">proprietary</font> ACT     platform, a <font color="blue">therapeutic</font> approach that seeks to harness the cell’s natural     defense mechanism against DNA damage</td>
    </tr>
    <tr>
      <td>Our second clinical-stage product     candidate, ARQ 197, is <font color="blue">based on</font> our c-Met/Cancer Survival platform, which is     designed to <font color="blue">block cancer cell survival mechanisms</font> and <font color="blue">thereby trigger death</font>     in <font color="blue">cancer cells</font></td>
    </tr>
    <tr>
      <td>We have not, nor to our knowledge has any other company,     received <font color="blue"><font color="blue">regulatory</font> approval</font> for a drug <font color="blue">based on</font> these approaches</td>
    </tr>
    <tr>
      <td>There can     be  no  assurance  that our <font color="blue">approaches will lead</font> to the <font color="blue">development</font> of     approvable or <font color="blue">marketable drugs</font></td>
    </tr>
    <tr>
      <td>We must show the safety and efficacy of our <font color="blue">product candidate</font>s through     expensive, time <font color="blue">consuming preclinical</font> and <font color="blue">clinical trials</font>, the results of     which are uncertain and <font color="blue">governed by exacting <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product candidate</font>s are in clinical or <font color="blue">preclinical stages</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Although our lead <font color="blue">product candidate</font> has <font color="blue">demonstrated</font> clinical tolerability,     favorable <font color="blue">pharmacokinetics</font> and evidence of anti-tumor activity in Phase 1     trials, and although our second clinical-stage product has <font color="blue">demonstrated</font> some     favorable <font color="blue">pharmacological effects</font> in <font color="blue">pre<font color="blue">clinical studies</font></font>, these <font color="blue">products may</font>     not  prove to be <font color="blue">sufficiently safe</font> or <font color="blue">effective</font> in more <font color="blue">advanced human</font>     clinical  trials, if at all</td>
    </tr>
    <tr>
      <td>We will need to conduct extensive further     testing of all of our <font color="blue">product candidate</font>s, expend <font color="blue">significant</font> <font color="blue">additional</font>     resources and <font color="blue">possibly partner with</font> another company (as we have done with     <font color="blue">Roche for ARQ </font>501) to realize <font color="blue">commercial <font color="blue">value from</font></font> any of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Before  obtaining  <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> for the <font color="blue">commercial sale</font> of our     products, we must demonstrate through <font color="blue">pre<font color="blue">clinical studies</font></font> (laboratory or     animal  testing) and <font color="blue">clinical trials</font> (human testing) that our proposed     products are safe and <font color="blue">effective</font> for use in <font color="blue">each target indication</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>testing is expensive and time-consuming, and failure can occur at any stage</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptable </font>results from initial <font color="blue">pre<font color="blue">clinical studies</font></font> and <font color="blue">clinical trials</font> of     products under <font color="blue">development</font> are not <font color="blue">necessarily indicative</font> of results that     will be obtained <font color="blue">from subsequent</font> or more extensive <font color="blue">pre<font color="blue">clinical studies</font></font> and     <font color="blue">clinical testing</font> in humans</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials may</font> not <font color="blue">demonstrate sufficient</font>     safety and efficacy to obtain the required <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> or result in     <font color="blue">marketable products</font></td>
    </tr>
    <tr>
      <td>The failure to <font color="blue"><font color="blue">adequately</font> demonstrate</font> the safety and     efficacy of a product under <font color="blue">development</font> will delay and <font color="blue">could prevent</font> its     <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>A  number  of  companies  in  the  <font color="blue">pharmaceutical</font>  industry, including     <font color="blue">bio<font color="blue">technology</font> companies</font>, have <font color="blue">suffered <font color="blue">significant</font> setbacks</font> in advanced     <font color="blue">clinical trials</font>, even after promising results in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>Though it is our stated strategy to pursue clinical <font color="blue">development</font> to take     advantage of available accelerated <font color="blue"><font color="blue">regulatory</font> approval</font> processes, there is     no guarantee that our <font color="blue"><font color="blue">product candidate</font>s will</font> show the <font color="blue">evidence predictive</font>     of <font color="blue">clinical benefit <font color="blue">necessary</font></font> to qualify for <font color="blue">such <font color="blue">regulatory</font> treatment</font></td>
    </tr>
    <tr>
      <td>Delays in <font color="blue">clinical testing</font> could result in increased costs to us and delay     our ability to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> and <font color="blue">commercialize</font> our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We cannot be assured of <font color="blue">successfully</font> completing <font color="blue">clinical testing</font> within the     time frame we have planned, or at all</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">numerous unforeseen</font>     <font color="blue">events during</font>, or as a result of, the clinical       17     ______________________________________________________________________       trial process that <font color="blue">could delay</font> or <font color="blue">prevent us from</font> receiving <font color="blue">regulatory</font>     approval or <font color="blue">commercializing</font> our <font color="blue">product candidate</font>s, including the following:       ·       our <font color="blue">clinical trials</font> may produce negative or <font color="blue">inconclusive</font> results,     and we may decide, or <font color="blue">regulators may</font> require us, to <font color="blue">conduct <font color="blue">additional</font></font>     clinical and/or pre-<font color="blue">clinical testing</font> or to <font color="blue">abandon programs</font>;       ·       trial results may not meet the level of <font color="blue">statistical significance</font>     required by the FDA or other <font color="blue">regulatory</font> agencies;       ·       <font color="blue">enrollment</font> in our <font color="blue">clinical trials</font> for our <font color="blue">product candidate</font>s may be     <font color="blue">slower than</font> we anticipate, resulting in <font color="blue"><font color="blue">significant</font> delays</font>;       ·       we, or regulators, may suspend or terminate our <font color="blue">clinical trials</font> if     the <font color="blue"><font color="blue">participating</font> patients</font> are being exposed to unacceptable <font color="blue">health risks</font>;       ·       the effects of our <font color="blue">product candidate</font>s on patients may not be the     desired  effects  or  may  include  undesirable  side effects or other     <font color="blue">characteristics</font> that may delay or preclude <font color="blue"><font color="blue">regulatory</font> approval</font> or limit     their <font color="blue">commercial use</font>, if approved; and       ·        the  FDA  or other <font color="blue">regulatory</font> agencies may lack experience in     evaluating  the safety and efficacy of drugs <font color="blue">based on</font> the ACT or c-Met     platforms, which could lengthen the <font color="blue">regulatory</font> review process</td>
    </tr>
    <tr>
      <td><font color="blue">Completion </font>of <font color="blue">clinical trials</font> depends, among other things, on our ability to     enroll a sufficient number of patients, which is a function of many factors,     including:       ·       the incidence among the general population of diseases which contain     <font color="blue">therapeutic</font> <font color="blue">endpoints</font> chosen for <font color="blue">evaluation</font>;       ·       the <font color="blue">eligibility</font> criteria defined in the protocol;       ·       the size of the <font color="blue">patient population</font> required for analysis of the     trial’s <font color="blue">therapeutic</font> <font color="blue">endpoints</font>;       ·       our ability to <font color="blue">recruit clinical trial investigators</font> and sites with     the <font color="blue"><font color="blue">appropriate</font> competencies</font> and experience;       ·       our ability to obtain and maintain <font color="blue">patient consents</font>; and       ·        <font color="blue">competition</font> for <font color="blue">patients by clinical trial programs</font> for other     <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>We primarily rely on third-parties to <font color="blue">provide sufficient quantities</font> of our     <font color="blue">product candidate</font>s to conduct pre-clinical and <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>We have no     <font color="blue">control over</font> our <font color="blue"><font color="blue">manufacture</font>rs</font>’ and suppliers’ <font color="blue">compliance with</font> <font color="blue">manufacturing</font>     <font color="blue">regulations</font>, and their failure to <font color="blue">comply could</font> result in an <font color="blue">interruption</font> in     the supply of our <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">facilities</font> used by</font> our contract <font color="blue"><font color="blue">manufacture</font>rs</font> must undergo an inspection     by the FDA for <font color="blue">compliance with</font> current good <font color="blue">manufacturing</font> practice, or cGMP,     <font color="blue">regulations</font>  before  the <font color="blue">product candidate</font>s produced there can receive     marketing  approval</td>
    </tr>
    <tr>
      <td>In  the  event these <font color="blue">facilities</font> do not receive a     satisfactory cGMP inspection result in <font color="blue">connection</font> with the <font color="blue">manufacture</font> of     our  product  <font color="blue">candidates</font>, we may need to <font color="blue">conduct <font color="blue">additional</font></font> <font color="blue">validation</font>     studies, or find <font color="blue">alternative</font> <font color="blue">manufacturing</font> <font color="blue">facilities</font>, either of which would     result in <font color="blue">significant</font> cost to us as well as a delay of up to <font color="blue">several years</font>     in obtaining approval for any affected <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>In addition, after     approval  of  a  product  candidate  for  commercial  use our contract     <font color="blue"><font color="blue">manufacture</font>rs</font>, and any <font color="blue">alternative</font> contract <font color="blue">manufacture</font>r we <font color="blue">may utilize</font>,     will be subject to <font color="blue">ongoing periodic inspection by</font> the FDA and <font color="blue">corresponding</font>     state and foreign agencies for <font color="blue">compliance with</font> cGMP <font color="blue">regulations</font>, similar     foreign <font color="blue">regulations</font> and other <font color="blue">regulatory</font> standards</td>
    </tr>
    <tr>
      <td>We do not have control     over our contract <font color="blue"><font color="blue">manufacture</font>rs</font>’ <font color="blue">compliance with</font> these <font color="blue">regulations</font> and     standards</td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure by</font> our third-party <font color="blue"><font color="blue">manufacture</font>rs</font> or suppliers to     <font color="blue">comply with</font> applicable <font color="blue">regulations</font> could result in sanctions being imposed     on them (including fines, injunctions and civil penalties), failure of     <font color="blue">regulatory</font> <font color="blue">authorities</font> to grant       18     ______________________________________________________________________       marketing  approval  of  our <font color="blue">product candidate</font>s, delays, suspension or     withdrawal of approvals, license revocation, seizures or recalls of product     <font color="blue">candidates</font> or products, operating <font color="blue">restrictions</font> and <font color="blue">criminal <font color="blue">prosecution</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on third parties</font> to <font color="blue">conduct most</font> of our <font color="blue">clinical trials</font>, and their     failure to perform their <font color="blue">obligations</font> in a timely or <font color="blue">competent manner may</font>     delay <font color="blue">development</font> and <font color="blue">commercialization</font> of our <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>We are using third-party clinical research <font color="blue">organizations</font> to <font color="blue">oversee most</font> of     our  ongoing  clinical  trials  and  expect to use the same or similar     <font color="blue">organizations</font> for our future <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may face delays outside</font> of     our control if these parties do not perform their <font color="blue">obligations</font> in a timely or     <font color="blue">competent fashion</font> or if we are forced to change <font color="blue">service providers</font></td>
    </tr>
    <tr>
      <td>This risk     is heightened if we conduct <font color="blue">clinical trials</font> outside of the United States,     where it may be more <font color="blue">difficult</font> to ensure that studies are conducted in     <font color="blue">compliance with</font> FDA <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Any third-party that we hire to conduct     <font color="blue">clinical trials</font> may also provide services to our <font color="blue">competitors</font>, which could     compromise the performance of their <font color="blue">obligations</font> to us</td>
    </tr>
    <tr>
      <td>If we experience     <font color="blue"><font color="blue">significant</font> delays</font> in the progress of our <font color="blue">clinical trials</font> and in our plans     to file NDAs, the commercial prospects for <font color="blue">product candidate</font>s could be     harmed and our ability to generate product revenue would be delayed or     prevented</td>
    </tr>
    <tr>
      <td>If we choose to acquire <font color="blue">complementary businesses</font>, products or <font color="blue">technologies</font>     instead of developing <font color="blue">them ourselves</font>, we may be unable to complete these     <font color="blue"><font color="blue">acquisition</font>s</font>,  to  integrate such <font color="blue"><font color="blue">acquisition</font>s</font> in a cost-<font color="blue">effective</font> and     non-disruptive  manner or to complete <font color="blue">commercialization</font> of an acquired     product</td>
    </tr>
    <tr>
      <td>From  time to time, we may choose to acquire <font color="blue">complementary businesses</font>,     products, or <font color="blue">technologies</font> instead of developing <font color="blue">them ourselves</font></td>
    </tr>
    <tr>
      <td>We do not     know if we will be able to complete any particular <font color="blue"><font color="blue">acquisition</font>s</font>, or whether     we will be able to <font color="blue">successfully</font> integrate the acquired business, operate it     profitably or retain its <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td><font color="blue">Integrating </font>any business, product or     <font color="blue">technology</font> we acquire could be expensive and time-consuming, disrupt our     ongoing business and distract company <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>In addition, in order to     finance any <font color="blue">acquisition</font>, we might need to raise <font color="blue">additional</font> funds through     public or <font color="blue">private equity</font> or <font color="blue">debt financings</font></td>
    </tr>
    <tr>
      <td>In that event, we could be     forced to obtain <font color="blue">financing on less than</font> favorable terms</td>
    </tr>
    <tr>
      <td>In the case of     equity  financing, that may result in dilution to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In     addition, under certain circumstances, amortization of assets or charges     resulting  from  the costs of <font color="blue"><font color="blue">acquisition</font>s</font> could harm our business and     operating results</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">find <font color="blue">collaborators</font></font> or <font color="blue">successfully</font> form <font color="blue"><font color="blue">collaboration</font>s</font>     to further our drug <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>As we did with ARQ 501, we <font color="blue">may seek <font color="blue">collaborators</font></font> for our drug <font color="blue">development</font>     efforts</td>
    </tr>
    <tr>
      <td>We <font color="blue">may <font color="blue">enter into</font></font> these <font color="blue"><font color="blue">collaboration</font>s</font> to obtain <font color="blue">external financing</font>     for drug <font color="blue">development</font> and to obtain access to <font color="blue">commercialization</font> expertise</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of <font color="blue">partners depends on</font> the <font color="blue">willingness</font> of <font color="blue">pharmaceutical</font>     companies to <font color="blue">collaborate</font> in drug <font color="blue">discovery</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Only a limited number     of <font color="blue">pharmaceutical</font> companies would fit our <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The number could     <font color="blue">decline further through consolidation</font>, or the number of <font color="blue"><font color="blue">collaborators</font> with</font>     interest  in  our  <font color="blue">drugs could decline</font></td>
    </tr>
    <tr>
      <td>If the number of our potential     <font color="blue">collaborators</font> declines further, <font color="blue">collaborators</font> may be able to negotiate terms     unfavorable to us</td>
    </tr>
    <tr>
      <td>We face <font color="blue">significant</font> <font color="blue">competition</font> in seeking drug <font color="blue">development</font> <font color="blue">collaborators</font>,     both from other <font color="blue">bio<font color="blue">technology</font> companies</font> and from the <font color="blue">internal capabilities</font>     and <font color="blue">compound pipelines</font> of the <font color="blue">pharmaceutical</font> companies themselves</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">competition</font> is <font color="blue">particularly intense</font> in the <font color="blue">oncology field</font></td>
    </tr>
    <tr>
      <td>Our ability to     interest such companies in forming co-<font color="blue">development</font> and <font color="blue">commercialization</font>     <font color="blue"><font color="blue">arrangements</font> with us will</font> be influenced by, among other things:       ·       the <font color="blue">compatibility</font> of <font color="blue">technologies</font>;       ·        the  potential  partner’s  <font color="blue">acceptance</font> of our approach to drug     <font color="blue">discovery</font>;       19     ______________________________________________________________________       ·       the quality and <font color="blue">commercial potential</font> of any <font color="blue">drug candidate</font> we may     succeed in developing; and       ·       our ability, and <font color="blue">collaborators</font>’ perceptions of our ability, to     achieve intended results in a timely fashion, with acceptable quality and     cost</td>
    </tr>
    <tr>
      <td>Even if we are able to gain the interest of <font color="blue">potential drug</font> <font color="blue">development</font>     partners, the negotiation, documentation and <font color="blue">implementation</font> of <font color="blue">collaborative</font>     <font color="blue">arrangements</font> are complex and time-consuming</td>
    </tr>
    <tr>
      <td><font color="blue">Collaborations </font>may not be     available  <font color="blue">on <font color="blue">commercially</font></font> acceptable terms and, if formed, may not be     <font color="blue"><font color="blue">commercially</font> successful</font> or, if successful, may not realize <font color="blue">sufficient return</font>     for us</td>
    </tr>
    <tr>
      <td>If we are unable to form <font color="blue"><font color="blue">collaboration</font>s</font>, we may not <font color="blue">gain access</font> to     the <font color="blue">financial resources</font> and <font color="blue">industry expertise <font color="blue">necessary</font></font> to develop drug     products or <font color="blue">successfully</font> market any products we develop on our own and,     therefore, be unable to generate <font color="blue">revenue from</font> <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> the efforts of our <font color="blue">collaborators</font>, whom we do not and     <font color="blue">cannot control</font></td>
    </tr>
    <tr>
      <td>If  we  are  able to <font color="blue">enter into</font> <font color="blue"><font color="blue">collaboration</font>s</font> for the <font color="blue">development</font> and     <font color="blue">commercialization</font> of our <font color="blue">product candidate</font>s, we <font color="blue">will depend on</font> our partners     to develop and <font color="blue">commercialize</font> our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Similarly, we currently     <font color="blue">depend on parties</font> to whom we have <font color="blue">provided compounds through <font color="blue">chemistry</font></font>     services <font color="blue"><font color="blue">collaboration</font>s</font> to develop and <font color="blue">commercialize</font> those compounds</td>
    </tr>
    <tr>
      <td>Our     drug <font color="blue">development</font> and <font color="blue">chemistry</font> services <font color="blue">collaborators</font> have <font color="blue">significant</font>     <font color="blue">discretion</font> in determining the efforts and resources that they will apply to     the <font color="blue">development</font> and <font color="blue">commercialization</font> of compounds and drug <font color="blue">candidates</font>     <font color="blue">covered by</font> their <font color="blue"><font color="blue">collaboration</font>s</font> with us</td>
    </tr>
    <tr>
      <td>We may not receive any further milestone, royalty or <font color="blue">license payments under</font>     our current or any future <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>Although we have received license fees, milestone fees and other payments to     <font color="blue">date under</font> our drug <font color="blue">development</font> and <font color="blue">chemistry</font> services <font color="blue"><font color="blue">collaboration</font>s</font>, we     may never receive any <font color="blue">royalty payments</font> or <font color="blue">additional</font> license and milestone     <font color="blue">fees under such agreements</font></td>
    </tr>
    <tr>
      <td>Our receipt of any future milestone, royalty or     license  payments  depends  on  many  factors,  including  whether our     <font color="blue">collaborators</font>  want or are able to continue to pursue a <font color="blue">potential drug</font>     candidate, unforeseen complications in the <font color="blue">development</font> or <font color="blue">commercialization</font>     process, and the <font color="blue">ultimate commercial success</font> of the drug</td>
    </tr>
    <tr>
      <td>Even  if  we  are  successful  in <font color="blue">bringing products</font> to market, we face     substantial <font color="blue">competitive challenges</font> in <font color="blue">effective</font>ly marketing and <font color="blue">distributing</font>     our products</td>
    </tr>
    <tr>
      <td>Many other companies and <font color="blue">research institutions</font> are developing     products  within the field of oncology, including large <font color="blue">pharmaceutical</font>     companies with much greater <font color="blue">financial resources</font>, and more experience in     developing products, running <font color="blue">clinical trials</font>, obtaining FDA approval and     bringing  new  drugs  to market</td>
    </tr>
    <tr>
      <td>We are in a <font color="blue">rapidly evolving field</font> of     research</td>
    </tr>
    <tr>
      <td>Consequently, our <font color="blue">technology</font> may be rendered non-competitive or     <font color="blue">obsolete by approaches</font> and methodologies dis<font color="blue">covered by</font> others, both before     and after we have gone to <font color="blue">market with</font> our products</td>
    </tr>
    <tr>
      <td>We also face <font color="blue">competition</font>     <font color="blue">from existing therapies</font> that are <font color="blue">currently accepted</font> in the marketplace, and     the  impact  of <font color="blue">adverse events</font> in our field that may affect <font color="blue">regulatory</font>     approval or <font color="blue">public perception</font></td>
    </tr>
    <tr>
      <td>Cost <font color="blue">containment pressures may affect</font> the <font color="blue">commercialization</font> of, and the     <font color="blue">revenues generated by</font>, our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> be subject to <font color="blue">cost containment pressures</font></td>
    </tr>
    <tr>
      <td>Even if our drugs     represent  <font color="blue">improvements</font>  over competitive therapies, pharmaco-economic     considerations may preclude <font color="blue"><font color="blue">regulatory</font> approval</font> or limit or <font color="blue">preclude patient</font>     <font color="blue">reimbursement</font>  by  third-party  or <font color="blue">government payors</font></td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">methodology used</font> in cost-benefit analyses of <font color="blue">drug use may</font> change, and we     <font color="blue">cannot predict</font> the impact of these changes upon <font color="blue">reimbursement</font> levels for our     products</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       We may not be able to recruit and retain the <font color="blue">scientists</font> and <font color="blue">management</font> we     need to compete</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our ability to attract, retain and <font color="blue">motivate highly</font>     <font color="blue">skilled scientific personnel</font> and <font color="blue">management</font>, and our ability to develop and     maintain  important  <font color="blue">relationships with leading academic institutions</font>,     <font color="blue">clinicians</font> and <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> our senior <font color="blue">management</font>     and <font color="blue">scientific staff</font>, and the loss of the services of one or more of our     other  key  employees  <font color="blue">could delay</font> or have an <font color="blue">impact on</font> the successful     <font color="blue">completion</font> of our <font color="blue">clinical trials</font> or the <font color="blue">commercialization</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We  compete intensely with <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font>,     including our <font color="blue">collaborators</font>, medicinal <font color="blue">chemistry</font> outsourcing companies,     <font color="blue">contract research companies</font>, and academic and <font color="blue">research institutions</font> to     recruit <font color="blue">scientists</font> and <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>The shortage of <font color="blue">personnel with</font> experience     in drug <font color="blue">development</font> could lead to increased recruiting, relocation and     compensation costs, which may exceed our expectations and resources</td>
    </tr>
    <tr>
      <td>If we     cannot hire <font color="blue">additional</font> qualified personnel, the <font color="blue">workload may increase</font> for     <font color="blue">both existing</font> and <font color="blue">new personnel</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in our <font color="blue">recruitment</font>     efforts, we may be unable to execute our strategy</td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">potential liability</font> related to the <font color="blue">development</font>, testing     or <font color="blue">manufacturing</font> of compounds we develop</td>
    </tr>
    <tr>
      <td>We are developing, <font color="blue">clinically testing</font> and <font color="blue">manufacturing</font> <font color="blue">therapeutic</font> products     for use in humans</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection</font> with these <font color="blue">activities</font>, we could be liable     if persons are injured or die <font color="blue">while using</font> these drugs</td>
    </tr>
    <tr>
      <td>We may have to pay     substantial damages and/or incur legal costs to defend claims resulting from     injury  or death, and we may not receive expected royalty or milestone     payments if <font color="blue">commercialization</font> of a drug is limited or ended as a result of     such claims</td>
    </tr>
    <tr>
      <td>We have <font color="blue">product liability</font> and <font color="blue">clinical trial insurance</font> that     contains  customary exclusions and <font color="blue">provides coverage per occurrence at</font>     levels, in the aggregate, which we believe are customary and <font color="blue">commercially</font>     reasonable  in  our  <font color="blue">industry given</font> the stage we have achieved in drug     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>However, our <font color="blue">product liability</font> insurance does not <font color="blue">cover every</font>     type of <font color="blue">product liability</font> claim that we may face or loss we may incur and     may not <font color="blue"><font color="blue">adequately</font> compensate us</font> for the <font color="blue">entire amount</font> of covered claims or     losses or for the harm to our business reputation</td>
    </tr>
    <tr>
      <td>Also, we may be unable to     maintain our <font color="blue">current insurance policies</font> or obtain and maintain <font color="blue">necessary</font>     <font color="blue">additional</font> coverage at acceptable costs, or at all</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR FINANCIAL CONDITION       We have incurred <font color="blue">significant</font> losses since our inception and anticipate that     we will incur <font color="blue">significant</font> continued losses for the <font color="blue">next <font color="blue">several years</font></font>, and     our <font color="blue">future <font color="blue">profitability</font></font> is uncertain</td>
    </tr>
    <tr>
      <td>From our inception in 1993 through <font color="blue">December </font>31, 2005, we have incurred     <font color="blue">cumulative losses</font> of approximately dlra197 million</td>
    </tr>
    <tr>
      <td>These losses have resulted     <font color="blue">principally</font>  from  the costs of our research <font color="blue">activities</font>, <font color="blue"><font color="blue">acquisition</font>s</font>,     <font color="blue">enhancements</font> to our <font color="blue">technology</font> and early-stage <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>In addition,     we expect <font color="blue">future expense</font> to increase <font color="blue">significant</font>ly as we <font color="blue">conduct larger</font> and     more advanced <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We have derived our <font color="blue">revenue primarily from</font>:       ·       license and <font color="blue">technology</font> transfer fees for access to our chemical     synthesis  and  production  platforms  such  as  transfer  of  certain     <font color="blue">chemistry</font>-related <font color="blue">technology</font> to Pfizer;       ·       payments for <font color="blue">product deliveries</font> in <font color="blue">connection</font> with our <font color="blue">chemistry</font>     services business;       ·       research and <font color="blue">development</font> funding paid under our <font color="blue">agreements with</font>     <font color="blue"><font color="blue">collaboration</font> partners</font>; and       ·       to a limited extent, milestone payments</td>
    </tr>
    <tr>
      <td>To date, these revenues have <font color="blue">generated profits only</font> in 1997 and 2000</td>
    </tr>
    <tr>
      <td>We     have not realized any <font color="blue"><font color="blue">revenue from</font> royalties from</font> the sale by any of our     <font color="blue">collaboration</font>  partners  of  a  <font color="blue">commercial product</font> developed using our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, following our decision to exit our <font color="blue">chemistry</font>     services business and Pfizer’s       21     ______________________________________________________________________       election to terminate our agreement <font color="blue">effective</font> May 22, 2006, we do not expect     to  receive <font color="blue">revenue from</font> that business following the <font color="blue">effective</font> date of     <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  have hired an <font color="blue">investment bank</font> to explore a     <font color="blue">potential sale</font> of our <font color="blue">chemistry</font> services business, we may not realize any     <font color="blue">value from</font> the <font color="blue">disposition</font> of these <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As a result, we expect to     record increased losses in the future <font color="blue">based on</font> cessation of these revenues     and on anticipated <font color="blue">increasing costs associated with</font> the <font color="blue">clinical testing</font> of     our products</td>
    </tr>
    <tr>
      <td>To  attain  <font color="blue">profitability</font>,  we  will need to develop <font color="blue">clinical products</font>     <font color="blue">successfully</font> and market and sell them <font color="blue">effective</font>ly, either by ourselves or     with   <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>We  have  never  generated  revenue  from  the     <font color="blue">commercialization</font> of our <font color="blue">product candidate</font>s, and there is no guarantee that     we will be able to do so in the future</td>
    </tr>
    <tr>
      <td>If our current <font color="blue">product candidate</font>s     fail to show positive results in our ongoing <font color="blue">clinical trials</font>, or we do not     receive <font color="blue"><font color="blue">regulatory</font> approval</font>, or if these <font color="blue">product candidate</font>s do not achieve     market <font color="blue">acceptance</font> even if approved, we may not <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>If we fail     to <font color="blue">become profitable</font>, or if we are unable to fund our <font color="blue">continuing losses</font>, we     may be unable to continue our clinical <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We  may need substantial <font color="blue">additional</font> funding and may be unable to raise     capital when needed, or on terms favorable to us, which could force us to     delay, reduce or eliminate our drug <font color="blue">discovery</font>, product <font color="blue">development</font> and     <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developing </font>drugs, conducting <font color="blue">clinical trials</font>, and <font color="blue">commercializing</font> products     is expensive</td>
    </tr>
    <tr>
      <td>Our future funding <font color="blue">requirements</font> <font color="blue">will depend on</font> many factors,     including:       ·        the terms and timing of any <font color="blue">collaborative</font>, licensing, <font color="blue">acquisition</font>     or other <font color="blue">arrangements</font> that we <font color="blue">may establish</font>;       ·        the progress and cost of our <font color="blue">clinical trials</font> and other research and     <font color="blue">development</font> <font color="blue">activities</font>;       ·        the costs and timing of obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>;       ·        the costs of filing, prosecuting, defending and enforcing any     <font color="blue">patent <font color="blue">applications</font></font>, claims, patents and other <font color="blue">intellectual property rights</font>;     and       ·        the cost and timing of securing <font color="blue">manufacturing</font> capabilities for our     clinical <font color="blue">product candidate</font>s and <font color="blue">commercial product</font>s, if any</td>
    </tr>
    <tr>
      <td>We believe our cash and <font color="blue">marketable securities at</font> <font color="blue">December </font>31, 2005 will be     sufficient to fund our projected operating <font color="blue">requirements</font> through at least     2007</td>
    </tr>
    <tr>
      <td>We have based this estimate <font color="blue">on assumptions</font> and estimates that may     prove to be wrong</td>
    </tr>
    <tr>
      <td>Even if our estimates are correct, we may choose to     obtain <font color="blue">additional</font> financing during that time</td>
    </tr>
    <tr>
      <td>It is likely we will need to raise <font color="blue">additional</font> capital or incur indebtedness     to continue to fund our <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td>Our ability to raise     <font color="blue">additional</font> funds <font color="blue">will depend on</font> financial, economic and <font color="blue">market conditions</font>     and other factors, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>There can be no     assurance that <font color="blue">sufficient funds will</font> be available to us when required, on     satisfactory terms, or at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">necessary</font> funds are not available, we may     have  to  delay, reduce the scope or eliminate some of our <font color="blue">development</font>     programs,  which <font color="blue">could delay</font> the time to market for any of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We may seek funds through <font color="blue">arrangements</font> with <font color="blue">collaborators</font> or others that may     require us to <font color="blue">relinquish rights</font> to certain <font color="blue">product candidate</font>s that we might     <font color="blue">otherwise seek</font> to develop or <font color="blue">commercialize</font> independently</td>
    </tr>
    <tr>
      <td>There can be no     assurance  that we will be able to <font color="blue">enter into</font> any such <font color="blue">arrangements</font> on     <font color="blue">reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       RISKS RELATED TO INTELLECTUAL PROPERTY       Our patents and other <font color="blue">proprietary</font> rights may fail to protect our business</td>
    </tr>
    <tr>
      <td>To be successful and compete, we must obtain and protect patents on our     products and <font color="blue">technology</font> and protect our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Where <font color="blue">appropriate</font>, we     seek  patent  protection  for <font color="blue">certain aspects</font> of the <font color="blue">technology</font> we are     developing, <font color="blue">but <font color="blue">patent protection</font> may</font> not be available for some of the     compounds  and  drugs,  and  their  use,  synthesis,  <font color="blue">formulations</font> and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The  patent  position  of bio<font color="blue">technology</font> firms is highly     uncertain, involves complex legal and factual questions, and has recently     been the subject of much <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>No <font color="blue">consistent policy</font> has <font color="blue">emerged from</font>     the <font color="blue">US Patent and Trademark Office </font>or the courts regarding the breadth of     claims allowed or the degree of <font color="blue">protection afforded under</font> many bio<font color="blue">technology</font>     patents</td>
    </tr>
    <tr>
      <td>In addition, there is a substantial backlog of bio<font color="blue">technology</font> patent     <font color="blue"><font color="blue">applications</font> at</font> the US Patent and Trademark Office, and the approval or     rejection of <font color="blue">patent <font color="blue">applications</font></font> may take <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We  do  not know whether our <font color="blue">patent <font color="blue">applications</font></font> will result in issued     patents</td>
    </tr>
    <tr>
      <td>In addition, the     receipt of a <font color="blue">patent might</font> not provide much <font color="blue">practical protection</font></td>
    </tr>
    <tr>
      <td>If we     receive a patent with a narrow scope, then it will be easier for <font color="blue">competitors</font>     to <font color="blue">design products</font> that do not <font color="blue">infringe on</font> our patent</td>
    </tr>
    <tr>
      <td>We cannot be certain     that we will receive any <font color="blue">additional</font> patents, that the claims of our patents     will offer <font color="blue">significant</font> protection of our <font color="blue">technology</font>, or that our patents     will not be challenged, narrowed, invalidated or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font><font color="blue">may interfere with</font> our <font color="blue">patent protection</font> in a variety of ways</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may claim that they invented the claimed <font color="blue">invention prior</font> to us</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may also claim that we are <font color="blue">infringing on</font> their patents and that,     therefore, we <font color="blue">cannot practice</font> our <font color="blue">technology</font> as claimed under our patents</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font><font color="blue">may also contest</font> our <font color="blue">patents by showing</font> the <font color="blue">patent examiner</font> that     the invention was not original, was not novel or was obvious</td>
    </tr>
    <tr>
      <td>In <font color="blue">litigation</font>,     a <font color="blue">competitor could</font> claim that our <font color="blue">issued patents</font> are not valid for a number     of reasons</td>
    </tr>
    <tr>
      <td>As a company, we     have <font color="blue">no meaningful</font> experience with <font color="blue">competitors</font> <font color="blue">interfering</font> with our patents     or <font color="blue">patent <font color="blue">applications</font></font> and therefore may not have the experience we would     need  to  <font color="blue">aggressively</font>  protect  our patents should such action become     <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>To protect or enforce our <font color="blue">patent rights</font>, we may initiate patent <font color="blue">litigation</font>     against  third  parties, such as <font color="blue">infringement</font> lawsuits or <font color="blue">interference</font>     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation</font> can be expensive, take <font color="blue">significant</font> time and     divert <font color="blue">management</font>’s attention from other business concerns, which could     increase  our  research  and <font color="blue">development</font> expense and delay our product     programs</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>that we <font color="blue">initiate may provoke third parties</font> to assert     claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also unclear whether</font> our <font color="blue">trade secrets</font> will prove to be <font color="blue">adequately</font>     protected</td>
    </tr>
    <tr>
      <td>To  protect  our  <font color="blue">trade secrets</font>, we require our employees,     <font color="blue">consultants</font> and advisors to execute <font color="blue"><font color="blue">confidential</font>ity agreements</font></td>
    </tr>
    <tr>
      <td>We cannot     guarantee, however, that these <font color="blue">agreements will provide us with adequate</font>     <font color="blue">protection against improper use</font> or <font color="blue">disclosure</font> of <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>Our employees, <font color="blue">consultants</font> or <font color="blue">advisors may unintentionally</font> or willfully     disclose our information to <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In addition, in some situations,     these <font color="blue">agreements may conflict with</font>, or be subject to, the rights of third     parties  with  whom our employees, <font color="blue">consultants</font> or advisors had or have     <font color="blue">previous employment</font> or <font color="blue">consulting relationships</font></td>
    </tr>
    <tr>
      <td>Like patent <font color="blue">litigation</font>,     enforcing a claim that a <font color="blue">third party illegally</font> obtained and is using our     trade  secrets  is  expensive  and  time-consuming, and the outcome is     unpredictable</td>
    </tr>
    <tr>
      <td>In addition, courts outside the <font color="blue">United States </font>are sometimes     <font color="blue">less willing than</font> our federal and state courts to protect <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">others may independently</font> develop <font color="blue">substantially equivalent</font>     knowledge, methods and know-how</td>
    </tr>
    <tr>
      <td>If  we must spend <font color="blue">significant</font> <font color="blue">additional</font> time and <font color="blue">money protecting</font> our     patents and <font color="blue">trade secrets</font>, we will have <font color="blue">fewer resources</font> to devote to the     <font color="blue">development</font> of our <font color="blue">technologies</font>, and our business and <font color="blue">financial prospects</font>     may be harmed</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       Our <font color="blue">success will depend partly on</font> our ability to operate <font color="blue">without infringing</font>     on or <font color="blue">misappropriating</font> the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>There are many patents in our field of <font color="blue">technology</font> and we <font color="blue">cannot guarantee</font>     that we do not <font color="blue">infringe on</font> those patents or that we will not <font color="blue">infringe on</font>     <font color="blue">patents granted</font> in the future</td>
    </tr>
    <tr>
      <td>If a <font color="blue">patent holder</font> believes a product of ours     infringes  on its patent, the <font color="blue">patent holder</font> may sue us even if we have     received  patent  protection for our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font>property     <font color="blue">litigation</font> is costly and, even if we prevail, the cost of such <font color="blue">litigation</font>     <font color="blue">could adversely affect</font> our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">litigation</font> is time-consuming and <font color="blue">could divert</font>     <font color="blue">management</font> attention and <font color="blue">resources away from</font> our business</td>
    </tr>
    <tr>
      <td>If we do not     prevail in <font color="blue">litigation</font>, we may have to pay substantial damages for past     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Also, if we lose, the <font color="blue">court may prohibit us from selling</font> or licensing the     product that infringes the patent unless the <font color="blue"><font color="blue">patent holder</font> licenses</font> the     patent to us</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent holder</font> is not required to grant us a license</td>
    </tr>
    <tr>
      <td>In addition, some <font color="blue">licenses may</font> be <font color="blue">nonexclusive</font> and,     <font color="blue">accordingly</font>, our <font color="blue">competitors</font> may have access to the same <font color="blue">technology</font> licensed     to us</td>
    </tr>
    <tr>
      <td>If we fail to obtain a required license, we <font color="blue">could encounter delays</font> in     product <font color="blue">development</font> while we attempt to <font color="blue">design around</font> other patents or we     <font color="blue">could even</font> be <font color="blue">prohibited from</font> developing, <font color="blue">manufacturing</font> or <font color="blue">selling products</font>     requiring these licenses</td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">occurrences</font> will result in lost revenues and     profits for us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> may restrict our use of scientific information</td>
    </tr>
    <tr>
      <td>The success of our <font color="blue">strategy depends</font>, in part, on our ability to apply a     <font color="blue">growing base</font> of knowledge, <font color="blue">technology</font> and <font color="blue">data across</font> all of our internal     projects  and  our <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>Some of this data has been and will     continue to be generated from our work with <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>We believe that     we have rights to use all such information <font color="blue">necessary</font> to our planned drug     <font color="blue">discovery</font> and <font color="blue">development</font> efforts; however, our <font color="blue">collaborators</font> may disagree     and may succeed in <font color="blue">preventing us from using</font> some or all of this information     and/or <font color="blue">technology</font> ourselves or <font color="blue">with others</font></td>
    </tr>
    <tr>
      <td>Without the ability to use this     information  freely,  we  may be limited in our ability to improve the     <font color="blue">efficiency</font> of our drug <font color="blue">discovery</font> and <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO REGULATION       We may not obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for the sale and <font color="blue">manufacture</font> of drug     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and <font color="blue">commercialization</font> of drug <font color="blue">candidates</font> in the United     States, including those drug <font color="blue">candidates</font> we develop alone or in <font color="blue">collaboration</font>     with our partners, are subject to extensive <font color="blue">regulation by</font> the FDA and other     <font color="blue">regulatory</font> agencies in the <font color="blue">United States </font>and by comparable <font color="blue">authorities</font> in     Europe and elsewhere</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>products require lengthy and costly     testing in animals and humans and <font color="blue"><font color="blue">regulatory</font> approval</font> by the <font color="blue">appropriate</font>     <font color="blue">governmental agencies prior</font> to <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities</font> may     suspend  <font color="blue">clinical trials</font> at any time if they believe that the subjects     <font color="blue">participating</font> in the trials are being exposed to unacceptable risks or if an     <font color="blue">agency finds deficiencies</font> in the conduct of the trials or other problems     with our product under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Approval of a <font color="blue">drug candidate</font> as safe and     <font color="blue">effective</font> for use in humans is <font color="blue">never certain</font> and these <font color="blue">agencies may delay</font> or     <font color="blue">deny approval</font> of the products for <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">regulatory</font>     policy during the period of <font color="blue">regulatory</font> review may result in unforeseen     delays or denial of approval</td>
    </tr>
    <tr>
      <td>Similar <font color="blue">regulations</font>, delays, denials and other     risks may be <font color="blue">encountered</font> in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>As a company, we have never obtained <font color="blue"><font color="blue">regulatory</font> approval</font> to <font color="blue">manufacture</font> and     sell a drug</td>
    </tr>
    <tr>
      <td>If we and/or our <font color="blue">collaborators</font> develop a <font color="blue">drug candidate</font> and     cannot  obtain  this approval, we may not realize milestone or royalty     payments  based  on  <font color="blue">commercialization</font>  goals for such <font color="blue">drug candidate</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>approval, if obtained, may be made subject to <font color="blue">limitations on</font> the     <font color="blue">indicated uses</font> for which we may market a       24     ______________________________________________________________________       product</td>
    </tr>
    <tr>
      <td>These limitations <font color="blue">could adversely affect</font> the <font color="blue">marketability</font> of our     <font color="blue">potential products</font> and <font color="blue">ultimately product revenues</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">regulatory</font>     approval is obtained, <font color="blue">regulatory</font> <font color="blue">authorities</font> may require <font color="blue">additional</font> clinical     studies, or specific risk <font color="blue">management</font> measures, after sales of a drug have     begun</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">identification</font> of certain side effects after a drug     is  on the <font color="blue">market may</font> result in the <font color="blue">subsequent withdrawal</font> of approval,     <font color="blue">reformulation</font> of the drug, <font color="blue">additional</font> preclinical and <font color="blue">clinical trials</font>,     changes in labeling, recalls, warnings to physicians or the public, negative     publicity, or the imposition of risk <font color="blue">management</font> measures that may limit our     ability to advertise or promote the product, restrict patient access to the     product, or otherwise have the effect of <font color="blue">reducing sales</font> of the product</td>
    </tr>
    <tr>
      <td>Furthermore,  for  any  marketed  product,  its  <font color="blue">manufacture</font>r  and its     <font color="blue">manufacturing</font> <font color="blue">facilities</font> will be subject to continual review and periodic     <font color="blue">inspections</font> by the FDA or other <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Failure to comply     with applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> may, among other things, result in     fines,  <font color="blue">suspensions</font>  of <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>, product recalls, product     seizures, operating <font color="blue">restrictions</font> and <font color="blue">criminal <font color="blue">prosecution</font></font></td>
    </tr>
    <tr>
      <td>Any of these events <font color="blue">could delay</font> or <font color="blue">prevent us from</font> <font color="blue">generating</font> <font color="blue">revenue from</font>     the <font color="blue">commercialization</font> of any drug <font color="blue">candidates</font> we develop or help to develop</td>
    </tr>
    <tr>
      <td>We have only limited experience in <font color="blue">regulatory</font> affairs, and some of our     <font color="blue">products may</font> be <font color="blue">based on</font> new <font color="blue">technologies</font>; these <font color="blue">factors may affect</font> our     ability or the time we require to obtain <font color="blue">necessary</font> <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font></td>
    </tr>
    <tr>
      <td>We have only recently initiated Phase 2 <font color="blue">clinical testing</font> with our lead     product and Phase 1 <font color="blue">clinical testing</font> with our <font color="blue">second product</font>, and we have     only limited experience in filing and prosecuting the <font color="blue">applications</font> <font color="blue">necessary</font>     to gain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font></td>
    </tr>
    <tr>
      <td>Moreover, certain of the products that are     likely to result from our research and <font color="blue">development</font> programs may be <font color="blue">based on</font>     new  <font color="blue">technologies</font>  and  new  <font color="blue">therapeutic</font> approaches that have not been     <font color="blue">extensively tested</font> in humans</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> <font color="blue">requirements</font> governing these     types of <font color="blue">products may</font> be more <font color="blue">rigorous than</font> for <font color="blue">conventional products</font></td>
    </tr>
    <tr>
      <td>As a     result, we may experience a longer <font color="blue">regulatory</font> process in <font color="blue">connection</font> with any     products that we develop <font color="blue">based on</font> these new <font color="blue">technologies</font> or new <font color="blue">therapeutic</font>     approaches</td>
    </tr>
    <tr>
      <td>RISKS RELATING TO HAZARDOUS WASTE       If our use of chemical and <font color="blue"><font color="blue">hazardous</font> materials violates applicable laws</font> or     causes <font color="blue">personal injury</font>, we may be liable for damages</td>
    </tr>
    <tr>
      <td>Our drug <font color="blue">discovery</font> <font color="blue">activities</font>, including the analysis and synthesis of     chemical compounds, involve the <font color="blue">controlled use</font> of <font color="blue">chemicals</font>, including     flammable, combustible, toxic and <font color="blue">radioactive materials</font> that are <font color="blue">potentially</font>     <font color="blue">hazardous</font> if misused</td>
    </tr>
    <tr>
      <td>Federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font> govern     our use, storage, handling and disposal of these materials</td>
    </tr>
    <tr>
      <td>These laws and     <font color="blue">regulations</font>  include  the  Resource Conservation and Recovery Act, the     <font color="blue">Occupational Safety and Health Act </font>and local fire and bpuilding codes, and     <font color="blue">regulations</font>  promulgated by the Department of Transportation, the Drug     Enforcement Agency, the Department of Energy, the Department of Health and     Human  Services,  and  the laws of Massachusetts, where we conduct our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may incur <font color="blue">significant</font> costs to <font color="blue">comply with</font> these laws and     <font color="blue">regulations</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font>our extensive <font color="blue">safety procedures</font>     for  handling  and disposing of <font color="blue">such materials</font>, the risk of <font color="blue"><font color="blue">accident</font>al</font>     <font color="blue">contamination</font>  or  injury  from  these  <font color="blue">materials cannot</font> be <font color="blue">completely</font>     eliminated</td>
    </tr>
    <tr>
      <td>In the event of an <font color="blue">accident</font>, our business could be disrupted and     we could be liable for damages, and any <font color="blue">such liability could exceed</font> our     resources, and have a negative <font color="blue">impact on</font> our <font color="blue">financial condition</font> and results     of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>